Speaker illustration

Associate Professor Jack Wei Chieh Tan

National Heart Centre Singapore, Singapore (Singapore)

Member of:

European Society of Cardiology

Dr Jack Tan is doubly accredited for cardiology and intensive care medicine in Singapore. He is the head of cardiology at the National Heart Centre Singapore and Sengkang General Hospital. He is a interventional cardiologist and holds adjunct associate professor appointments at Duke NUS and lecturer appointment at the Yong Loo Lin Medical School. Dr Jack Tan is the past president of the Singapore Cardiac Society 2018-2019, APSC (Asian Pacific Society of Cardiology) 2020-2021, ISCP (International Society of Cardiovascular Pharmacotherapy) 2021 and previous continental chair of the WHF (World Heart Federation) 2018. Currently he is an executive board member at Singapore Heart Foundation and APSIC (Asian Pacific Society of Interventional Cardiology) .

How to prepare for your Cardiology Exam? - Live discussion room

Event: ESC Asia with APSC & AFC 2021

Topic: European Society of Cardiology

Session type: Special Session

Thumbnail

APSC Consensus Statements session

Event: ESC Asia with APSC & AFC 2021

Topic: European Society of Cardiology

Session type: Expert Session

Thumbnail

Personalized Approaches to antiplatelet treatment in ACS-PCI patients

Event: ESC Asia with APSC & AFC 2021

Topic: Antiplatelet Agents

Session type: Satellite Symposium

Thumbnail

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt?

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardiovascular Disease in Special Populations

Session type: Official Joint Session

Thumbnail

Hot topics in Asia: cardiac care unit, COVID-19 and acute heart failure

Event: ACVC 2021

Topic: Acute Cardiac Care

Session type: Symposium

Thumbnail

Paradigm shifts in HFrEF management: SGLT2-Inhibitors

Event: ESC Asia with APSC & AFC 2020

Topic: Chronic Heart Failure

Session type: Industry Technology and Innovation session

Thumbnail

Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i

Event: ESC Asia with APSC & AFC 2020

Topic: Renal Failure and Cardiovascular Disease

Session type: Industry Technology and Innovation session

Thumbnail

Closing Session

Event: ESC Asia with APSC & AFC

Topic: Other

Session type: Special Session

Thumbnail

APSC Consensus Statements

Event: ESC Asia with APSC & AFC

Topic: Other

Session type: Special Session

Thumbnail

Understanding PCSK9 Inhibitors: what, when and why?

Event: ESC Asia with APSC & AFC

Topic: PCSK9-Antagonists

Session type: Satellite Symposium

Thumbnail

This platform is supported by

logo Novo Nordisk